← 產業報告目錄

HLA Typing Market by Technology (PCR (SSO, SSP, Real-time), Sequencing (NGS, Sanger's)), Product (Instruments, Reagents, Software), Application (Donor-recipient Cross-matching, Transfusion, Cancer), End User (Hospitals, Reference Labs) Global Forecasts to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-06-02頁數 267報告編號 MD7576

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global HLA typing market is projected to grow from USD 1.7 billion in 2025 to USD 2.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.0% over the forecast period from 2025 to 2030. Transplantation continues to be the preferred treatment option for many patients suffering from chronic dialysis-dependent end-stage renal disease, as well as those requiring heart, liver, or bone marrow transplants. Over the past decade, significant advancements have been made in HLA typing technologies, antibody monitoring, diagnostic methods, and specialized software developed by various companies. These innovations have become integral to the organ transplantation process, enhancing precision and reliability, and have played a key role in driving the expansion of the HLA typing market. The commercial service providers segment accounted for the highest growth rate in the HLA typing market, by product and service, during the forecast period. Based on end-user segmentation, the HLA (Human Leukocyte Antigen) typing market is categorized into commercial service providers, hospitals and transplant centers, and research laboratories and academic institutions. Among these, commercial service providers generated the highest revenue and are expected to witness strong growth, driven by the global rise in organ and stem cell transplants, which require precise, high-throughput HLA typing for effective donor-recipient matching. Growing awareness of personalized medicine, advancements in molecular diagnostics, and the increasing adoption of next-generation sequencing (NGS) technologies are key factors fueling demand for more specialized reagents and kits. . The diagnostic applications segment held the largest market share in 2024. The HLA typing market is categorized based on application into diagnostic applications—including donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy, and other diagnostic uses—and research applications. The diagnostic application segment is projected to dominate the market throughout the forecast period, with infectious disease testing accounting for the largest share within this segment. This is largely due to the heightened risk transplant recipients face of acquiring infections from donors. Current donor epidemiological screening methods and laboratory diagnostics have limitations in accurately assessing these risks, making infectious disease testing a critical and continuously growing focus area within the diagnostic segment of the transplant diagnostics market. The market in the North America region is expected to hold a significant market share for the HLA typing market in 2023. The HLA typing market spans five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In North America, the market is experiencing strong growth driven by the increasing demand for organ and stem cell transplants, the rising prevalence of chronic and autoimmune diseases, and the adoption of advanced molecular diagnostic techniques. This growth is further supported by a well-established healthcare infrastructure, government initiatives such as the National Marrow Donor Program, and greater public awareness of the importance of accurate HLA matching. The region is a hub for innovation and research, with many leading companies in the HLA typing space headquartered in the region. As a result, cutting-edge technologies, including next-generation sequencing (NGS), are being rapidly adopted, further fueling market expansion. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side: 60% and Demand Side: 40% • By Designation: Managers: 20%, CXOs & Directors: 30%, and Executives: 50% • By Region: North America: 40%, Europe: 30%, Asia Pacific: 20%, Latin America: 5%, and Middle East & Africa: 5% List of Key Companies Profiled in the Report The prominent players in the HLA typing market are Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), F. Hoffman-La Roche Ltd (Switzerland), Accelerate Diagnostics, Inc. (US), Alpha Biotech Limited (Israel), Bag Diagnostics GmbH (Germany), Caredx, Inc. (US), Creative Biolabs (US), Fujirebio Holdings Inc (Japan), Gendx (Netherlands), Hologic, Inc. (US), Histogenetics LLC (US), Hansa Biopharma AB (Sweden), Illumina, Inc. (US), Inno-Train Diagnostik GmbH (Germany), Immucor, Inc. (US), Krishgen Biosystems (India), Omixon Inc. (Hungary), PacBio (US), Proimmune Ltd (UK), Pacific Bioscience of California Inc. (US), TBG Diagnostics Limited (Australia), and Takara Bio Inc. (Japan), among others. Research Coverage This report studies the HLA typing market based on product & service, technology, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions). Reasons to buy this report The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall HLA typing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (growing number of organ transplantation procedures, rising technological advancements in HLA typing, increasing funding for research activities, growing prevalence of infectious diseases), restraints (high cost of HLA typing products, limited reimbursements for target procedures), opportunities (rising adoption of cross-matching and chimerism testing procedures, growing awareness of organ donations), and challenges (limited number of organ donations and long waiting lists for transplantations, shortage of skilled professionals) • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the HLA typing market • Market Development: Comprehensive information about lucrative markets • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HLA typing market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the HLA typing market.
目錄 Table of Contents
1 INTRODUCTION 26 1.1 STUDY OBJECTIVES 26 1.2 MARKET DEFINITION 26 1.3 STUDY SCOPE 27 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 27 1.3.2 INCLUSIONS AND EXCLUSIONS 28 1.3.3 YEARS CONSIDERED 28 1.4 CURRENCY CONSIDERED 28 1.5 STAKEHOLDERS 29 1.6 SUMMARY OF CHANGES 29 2 RESEARCH METHODOLOGY 30 2.1 RESEARCH DATA 30 2.1.1 SECONDARY DATA 31 2.1.1.1 Indicative list of secondary sources 32 2.1.1.2 Key data from secondary sources 32 2.1.2 PRIMARY DATA 33 2.1.2.1 Primary sources 33 2.1.2.2 Key data from primary sources 34 2.1.2.3 Key industry insights 34 2.1.2.4 Breakdown of primary interviews 35 2.2 MARKET SIZE ESTIMATION 35 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 37 2.2.2 END-USER-BASED MAPPING MARKET ESTIMATION 38 2.3 GROWTH FORECASTING MODEL 39 2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 41 2.5 RESEARCH ASSUMPTIONS 42 2.6 RESEARCH LIMITATIONS 42 2.7 RISK ANALYSIS 43 3 EXECUTIVE SUMMARY 44 4 PREMIUM INSIGHTS 48 4.1 HLA TYPING MARKET OVERVIEW 48 4.2 REGIONAL SNAPSHOT OF HLA TYPING MARKET 49   5 MARKET OVERVIEW 50 5.1 INTRODUCTION 50 5.2 MARKET DYNAMICS 50 5.2.1 DRIVERS 51 5.2.1.1 Rising number of organ transplantation procedures 51 5.2.1.2 Increasing technological advancements in sanger sequencing 52 5.2.1.3 Growing funding and research activities 52 5.2.1.4 Increasing prevalence of infectious and autoimmune diseases 53 5.2.2 RESTRAINTS 53 5.2.2.1 High cost of hla typing products 53 5.2.2.2 Limited reimbursement policies 54 5.2.3 OPPORTUNITIES 54 5.2.3.1 Adoption of cross-matching and chimerism testing 54 5.2.3.2 Growth opportunities in emerging markets 55 5.2.4 CHALLENGES 55 5.2.4.1 Shortage of skilled professionals 55 5.2.4.2 Lack of standardization across laboratories 56 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 56 5.4 PRICING ANALYSIS 57 5.4.1 AVERAGE SELLING PRICE, BY INSTRUMENTS 57 5.4.2 AVERAGE SELLING PRICE, BY REAGENTS 58 5.4.3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENTS 58 5.4.4 AVERAGE SELLING PRICE TREND, BY REGION 59 5.5 VALUE CHAIN ANALYSIS 60 5.5.1 R&D 60 5.5.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT 60 5.5.3 MARKETING, SALES, AND DISTRIBUTION 60 5.5.4 POST-SALES SERVICES 61 5.6 SUPPLY CHAIN ANALYSIS 61 5.6.1 PROMINENT COMPANIES 61 5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES 61 5.6.3 END USERS 62 5.7 ECOSYSTEM ANALYSIS 62 5.8 INVESTMENT AND FUNDING SCENARIO 63 5.9 TECHNOLOGY ANALYSIS 64 5.9.1 KEY TECHNOLOGIES 65 5.9.1.1 Sequence-based typing 65 5.9.1.2 Next-generation sequencing 65 5.9.2 COMPLEMENTARY TECHNOLOGIES 65 5.9.2.1 Sample preparation & dna extraction technologies 65 5.9.2.2 Bioinformatics and data analysis software 66 5.9.3 ADJACENT TECHNOLOGIES 66 5.9.3.1 Transplant diagnostics 66 5.10 PATENT ANALYSIS 66 5.11 TRADE ANALYSIS 68 5.11.1 IMPORT SCENARIO (HS CODE 3822) 68 5.11.2 EXPORT SCENARIO (HS CODE 3822) 70 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 71 5.13 CASE STUDY ANALYSIS 71 5.14 REGULATORY LANDSCAPE 73 5.14.1 REGULATORY GUIDELINES 73 5.14.1.1 North America 73 5.14.1.1.1 US 73 5.14.1.1.2 Canada 73 5.14.1.2 Europe 73 5.14.1.2.1 UK 73 5.14.1.2.2 France 73 5.14.1.2.3 Germany 74 5.14.1.3 Asia pacific 74 5.14.1.3.1 China 74 5.14.1.3.2 Japan 74 5.14.1.3.3 India 74 5.14.1.4 Latin America 74 5.14.1.4.1 Brazil 74 5.14.1.4.2 Mexico 75 5.14.1.5 Middle East & Africa 75 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 5.15 PORTER’S FIVE FORCE ANALYSIS 76 5.15.1 BARGAINING POWER OF SUPPLIERS 78 5.15.2 BARGAINING POWER OF BUYERS 78 5.15.3 THREAT OF NEW ENTRANTS 78 5.15.4 THREAT OF SUBSTITUTES 78 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 78 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 79 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 5.16.2 KEY BUYING CRITERIA 80 5.17 UNMET NEEDS 81 5.18 IMPACT OF AI ON HLA TYPING MARKET 81 5.18.1 INTRODUCTION 81 5.18.2 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE TRANSPLANT EVALUATION 82 5.18.3 AI USE CASES 82 5.18.4 KEY COMPANIES IMPLEMENTING AI 82 5.19 IMPACT OF 2025 US TARIFF 83 5.19.1 INTRODUCTION 83 5.19.2 KEY TARIFF RATES 83 5.19.3 PRICE IMPACT ANALYSIS 84 5.19.4 IMPACT ON COUNTRY/REGION 84 5.19.4.1 Us 84 5.19.4.2 Europe 84 5.19.4.3 Asia pacific 84 5.19.5 IMPACT ON END-USE INDUSTRIES 85 6 HLA TYPING MARKET, BY PRODUCT & SERVICE 86 6.1 INTRODUCTION 87 6.2 REAGENTS & CONSUMABLES 87 6.2.1 INCREASED DEMAND FOR SPECIALIZED CONSUMABLES TO DRIVE MARKET 87 6.3 INSTRUMENTS 88 6.3.1 NEED FOR DONOR-RECIPIENT MATCHING AND IMMUNOGENETIC RESEARCH TO AID GROWTH 88 6.4 SOFTWARE & SERVICES 89 6.4.1 GROWING DEMAND FOR ADVANCED AND USER-FRIENDLY SOFTWARE TO BOOST MARKET 89 7 HLA TYPING MARKET, BY TECHNOLOGY 91 7.1 INTRODUCTION 92 7.2 MOLECULAR ASSAY TECHNOLOGIES 92 7.2.1 PCR-BASED MOLECULAR ASSAYS 93 7.2.1.1 Sequence-specific primer-PCR 94 7.2.1.1.1 Higher speed, precision, and affordability to favor growth 94 7.2.1.2 Sequence-specific oligonucleotide-PCR 95 7.2.1.2.1 Growing applications of PCR in donor-recipient matching, cancer, rheumatoid, and arthritis to drive market 95 7.2.1.3 Real-time PCR 96 7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to facilitate growth 96 7.2.1.4 Other PCR-based molecular assays 97 7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 98 7.2.2.1 Sanger sequencing 99 7.2.2.1.1 Increasing use of sanger sequencing in clinical settings for organ and bone marrow transplantations to aid growth 99 7.2.2.2 Next-generation sequencing 100 7.2.2.2.1 Growing reliance on outsourcing to fuel market 100 7.2.2.3 Other sequencing-based molecular assays 101   7.3 NON-MOLECULAR ASSAY TECHNOLOGIES 102 7.3.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO AUGMENT GROWTH 102 8 HLA TYPING MARKET, BY APPLICATION 104 8.1 INTRODUCTION 105 8.2 DIAGNOSTIC APPLICATIONS 105 8.2.1 DONOR-RECIPIENT CROSS-MATCHING 106 8.2.1.1 Increasing focus on successful organ transplants to foster growth 106 8.2.2 INFECTIOUS DISEASE TESTING 107 8.2.2.1 Rising prevalence of infectious diseases to accelerate growth 107 8.2.3 CANCER DIAGNOSTIC & PREVENTION 108 8.2.3.1 Increasing demand for accurate and early cancer diagnosis to bolster growth 108 8.2.4 TRANSFUSION THERAPY 109 8.2.4.1 Growing clinical evidence supporting hla typing to propel market 109 8.2.5 OTHER DIAGNOSTIC APPLICATIONS 110 8.3 RESEARCH APPLICATIONS 111 8.3.1 EXPANDING USE OF GENOMIC TECHNOLOGIES TO EXPEDITE GROWTH 111 9 HLA TYPING MARKET, BY END USER 113 9.1 INTRODUCTION 114 9.2 COMMERCIAL SERVICE PROVIDERS 114 9.2.1 RISING DEMAND FOR OUTSOURCED SERVICES TO CONTRIBUTE TO GROWTH 114 9.3 HOSPITALS & TRANSPLANT CENTERS 115 9.3.1 GROWING DEMAND FOR ORGAN TRANSPLANTS TO BOOST MARKET 115 9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 116 9.4.1 INCREASING RESEARCH ACTIVITIES TO PROMOTE GROWTH 116 10 HLA TYPING MARKET, BY REGION 118 10.1 INTRODUCTION 119 10.2 NORTH AMERICA 120 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 120 10.2.2 US 124 10.2.2.1 Expanding donor registries and precision medicine to propel market 124 10.2.3 CANADA 126 10.2.3.1 Evolving healthcare landscape to augment growth 126 10.3 EUROPE 128 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 129 10.3.2 GERMANY 133 10.3.2.1 Growing investments in genomic research and digital healthcare to drive market 133   10.3.3 UK 135 10.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth 135 10.3.4 FRANCE 137 10.3.4.1 Growing adoption for donor-recipient compatibility testing to boost market 137 10.3.5 SPAIN 140 10.3.5.1 Increasing solid organ transplantation procedures to facilitate growth 140 10.3.6 ITALY 142 10.3.6.1 Supportive government policies and strong healthcare infrastructure to promote growth 142 10.3.7 REST OF EUROPE 144 10.4 ASIA PACIFIC 145 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 147 10.4.2 CHINA 151 10.4.2.1 Increasing utilization of hla typing for donor-recipient matching to propel market 151 10.4.3 JAPAN 153 10.4.3.1 Growing burden of chronic diseases to boost market 153 10.4.4 INDIA 155 10.4.4.1 Increasing government efforts to offer free access to support growth 155 10.4.5 SOUTH KOREA 157 10.4.5.1 Advanced healthcare to contribute to growth 157 10.4.6 AUSTRALIA 159 10.4.6.1 Increasing integration of genomic tools in diagnostics to promote growth 159 10.4.7 REST OF ASIA PACIFIC 161 10.5 LATIN AMERICA 163 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 163 10.5.2 BRAZIL 167 10.5.2.1 Growing adoption of next-generation sequencing to drive market 167 10.5.3 MEXICO 169 10.5.3.1 Supportive business environment to bolster growth 169 10.5.4 REST OF LATIN AMERICA 171 10.6 MIDDLE EAST & AFRICA 173 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 173 10.6.2 GCC COUNTRIES 177 10.6.2.1 Improvements in healthcare infrastructure to spur growth 177 10.6.3 REST OF MIDDLE EAST & AFRICA 179   11 COMPETITIVE LANDSCAPE 182 11.1 INTRODUCTION 182 11.2 KEY PLAYER STRATEGIES 182 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HLA TYPING MARKET 182 11.3 REVENUE ANALYSIS, 2020–2024 183 11.4 MARKET SHARE ANALYSIS, 2024 184 11.5 COMPANY VALUATION AND FINANCIAL METRICS 188 11.6 PRODUCT/BRAND COMPARISON 189 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 190 11.7.1 STARS 190 11.7.2 EMERGING LEADERS 190 11.7.3 PERVASIVE PLAYERS 190 11.7.4 PARTICIPANTS 190 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 192 11.7.5.1 Company footprint 192 11.7.5.2 Region footprint 193 11.7.5.3 Product footprint 194 11.7.5.4 Technology footprint 195 11.7.5.5 Application footprint 196 11.7.5.6 End-user footprint 197 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 198 11.8.1 PROGRESSIVE COMPANIES 198 11.8.2 RESPONSIVE COMPANIES 198 11.8.3 DYNAMIC COMPANIES 198 11.8.4 STARTING BLOCKS 198 11.8.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024 200 11.8.5.1 Detailed list of key startup/sme players 200 11.8.5.2 Competitive benchmarking of startups/smes 201 11.9 COMPETITIVE SCENARIO 201 11.9.1 PRODUCT LAUNCHES AND APPROVALS 201 11.9.2 DEALS 203 11.9.3 EXPANSIONS 205 12 COMPANY PROFILES 206 12.1 MAJOR PLAYER 206 12.1.1 BD 206 12.1.1.1 Business overview 206 12.1.1.2 Products offered 207 12.1.1.3 Mnm view 208 12.1.1.3.1 Key Strengths 208 12.1.1.3.2 Strategic choices 208 12.1.1.3.3 Weaknesses and competitive threats 208 12.1.2 THERMO FISHER SCIENTIFIC INC. 209 12.1.2.1 Business overview 209 12.1.2.2 Products offered 210 12.1.2.3 Recent developments 211 12.1.2.3.1 Product launches and approvals 211 12.1.2.3.2 Deals 212 12.1.2.3.3 Expansions 212 12.1.2.4 Mnm view 213 12.1.2.4.1 Key strengths 213 12.1.2.4.2 Strategic choices 213 12.1.2.4.3 Weaknesses and competitive threats 213 12.1.3 ILLUMINA, INC. 214 12.1.3.1 Business overview 214 12.1.3.2 Products offered 215 12.1.3.3 Recent developments 216 12.1.3.3.1 Expansions 216 12.1.3.4 Mnm view 216 12.1.3.4.1 Key strengths 216 12.1.3.4.2 Strategic choices 216 12.1.3.4.3 Weaknesses and competitive threats 217 12.1.4 QIAGEN 218 12.1.4.1 Business overview 218 12.1.4.2 Products offered 219 12.1.4.3 Recent developments 221 12.1.4.3.1 Product launches and approvals 221 12.1.4.3.2 Deals 222 12.1.4.4 Mnm view 222 12.1.4.4.1 Key strengths 222 12.1.4.4.2 Strategic choices 222 12.1.4.4.3 Weaknesses and competitive threats 222 12.1.5 BIO-RAD LABORATORIES, INC. 223 12.1.5.1 Business overview 223 12.1.5.2 Products offered 224 12.1.5.3 Recent developments 226 12.1.5.3.1 Product launches and approvals 226 12.1.5.4 Mnm view 226 12.1.5.4.1 Key strengths 226 12.1.5.4.2 Strategic choices 226 12.1.5.4.3 Weaknesses and competitive threats 226   12.1.6 F. HOFFMANN-LA ROCHE LTD 227 12.1.6.1 Business overview 227 12.1.6.2 Products offered 228 12.1.6.3 Recent developments 229 12.1.6.3.1 Product launches and approvals 229 12.1.6.3.2 Expansions 229 12.1.6.4 Mnm view 230 12.1.6.4.1 Key strengths 230 12.1.6.4.2 Strategic choices 230 12.1.6.4.3 Weaknesses and competitive threats 230 12.1.7 CAREDX, INC. 231 12.1.7.1 Business overview 231 12.1.7.2 Products offered 232 12.1.7.3 Recent developments 232 12.1.7.3.1 Product launches and approvals 232 12.1.7.3.2 Deals 233 12.1.8 WERFEN 234 12.1.8.1 Business overview 234 12.1.8.2 Products offered 234 12.1.8.3 Recent developments 235 12.1.8.3.1 Product launches and approvals 235 12.1.8.3.2 Deals 235 12.1.9 DIASORIN S.P.A. 236 12.1.9.1 Business overview 236 12.1.9.2 Products offered 237 12.1.9.3 Recent developments 237 12.1.9.3.1 Product launches and approvals 237 12.1.10 TBG BIOTECHNOLOGY CORPORATION 238 12.1.10.1 Business overview 238 12.1.10.2 Products offered 238 12.1.10.3 Recent developments 239 12.1.10.3.1 Product launches and approvals 239 12.1.10.3.2 Deals 239 12.1.11 FUJIREBIO 240 12.1.11.1 Business overview 240 12.1.11.2 Products offered 240 12.1.11.3 Recent developments 241 12.1.11.3.1 Deals 241 12.1.12 EUROBIO SCIENTIFIC 242 12.1.12.1 Business overview 242 12.1.12.2 Products offered 243 12.1.12.3 Recent developments 243 12.1.12.3.1 Product launches and approvals 243 12.1.12.3.2 Deals 244 12.1.13 PACBIO 245 12.1.13.1 Business overview 245 12.1.13.2 Products offered 246 12.1.13.3 Recent developments 247 12.1.13.3.1 Product launches and approvals 247 12.1.13.3.2 Deals 247 12.1.14 BAG DIAGNOSTICS GMBH 248 12.1.14.1 Business overview 248 12.1.14.2 Products offered 248 12.1.15 CREATIVE BIOLABS 249 12.1.15.1 Business overview 249 12.1.15.2 Products offered 249 12.2 OTHER PLAYERS 250 12.2.1 HISTOGENETICS LLC 250 12.2.2 SCISCO GENETICS, INC. 251 12.2.3 INNO-TRAIN DIAGNOSTIK GMBH 252 12.2.4 BIONOBIS 253 12.2.5 TAKARA BIO INC. 254 12.2.6 KRISHGEN BIOSYSTEMS 255 12.2.7 SCIENCELL RESEARCH LABORATORIES, INC. 256 12.2.8 PROIMMUNE LTD. 257 12.2.9 BIOFORTUNA LIMITED 258 12.2.10 ALPHA BIOTECH LIMITED 259 13 APPENDIX 260 13.1 DISCUSSION GUIDE 260 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 263 13.3 CUSTOMIZATION OPTIONS 265 13.4 RELATED REPORTS 265 13.5 AUTHOR DETAILS 266
圖表清單 List of Tables & Figures
TABLE 1 HLA TYPING MARKET: INCLUSIONS AND EXCLUSIONS 28 TABLE 2 HLA TYPING MARKET: RISK ANALYSIS 43 TABLE 3 HLA TYPING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 51 TABLE 4 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENTS, 2024 (USD) 58 TABLE 5 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 59 TABLE 6 HLA TYPING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 62 TABLE 7 HLA TYPING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025 68 TABLE 8 IMPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 69 TABLE 9 EXPORT SCENARIO FOR HS CODE 3822, BY COUNTRY, 2020–2024 (USD THOUSAND) 70 TABLE 10 HLA TYPING MARKET KEY CONFERENCES AND EVENTS, 2025–2026 71 TABLE 11 DEVELOPMENT AND IMPLEMENTATION OF INFORMATION SYSTEM FOR HLA TYPING LABORATORY MANAGEMENT 71 TABLE 12 IMPROVED HLA TYPING ACCURACY ACROSS DIVERSE SAMPLE TYPES USING SEQUENCING-BASED ASSAYS 72 TABLE 13 HIGH-RESOLUTION EXTENDED 6-LOCI HLA TYPING FOR IDENTIFYING RELATED DONORS IN INDIAN SUBCONTINENT 72 TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 18 HLA TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS 77 TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 79 TABLE 20 KEY BUYING CRITERIA FOR END USERS 80 TABLE 21 HLA TYPING MARKET: UNMET NEEDS 81 TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES 83 TABLE 23 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 87 TABLE 24 HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION) 88 TABLE 25 HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 89 TABLE 26 HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION) 90 TABLE 27 HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 92 TABLE 28 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 93 TABLE 29 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 93 TABLE 30 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 94 TABLE 31 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION) 94 TABLE 32 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2023–2030 (USD MILLION) 95 TABLE 33 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2023–2030 (USD MILLION) 96 TABLE 34 HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION, 2023–2030 (USD MILLION) 97 TABLE 35 HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 36 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 99 TABLE 37 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 38 HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 39 HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 40 HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 41 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 42 HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 105 TABLE 43 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 106 TABLE 44 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 45 HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 46 HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 47 HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 48 HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 49 HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 50 HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 51 HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 114 TABLE 52 HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 53 HLA TYPING MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 54 HLA TYPING MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 55 HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE, 2023 (NUMBER OF TRANSPLANTS) 119 TABLE 56 NORTH AMERICA: TRANSPLANT VOLUME, 2024 120 TABLE 57 NORTH AMERICA: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 58 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 122 TABLE 59 NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 122 TABLE 60 NORTH AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 122 TABLE 61 NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 123 TABLE 62 NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 123 TABLE 63 NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 123 TABLE 64 NORTH AMERICA: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 124 TABLE 65 NORTH AMERICA: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 124 TABLE 66 US: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 125 TABLE 67 US: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 68 US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 126 TABLE 69 US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 126 TABLE 70 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 127 TABLE 71 CANADA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 127 TABLE 72 CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 128 TABLE 73 CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 128 TABLE 74 EUROPE: TRANSPLANT VOLUME, 2024 129 TABLE 75 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 76 EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 130 TABLE 77 EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 130 TABLE 78 EUROPE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 79 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 80 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 132 TABLE 81 EUROPE: HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 132 TABLE 82 EUROPE: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 133 TABLE 83 EUROPE: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 133 TABLE 84 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 134 TABLE 85 GERMANY: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 86 GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 135 TABLE 87 GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 135 TABLE 88 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 136 TABLE 89 UK: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 136 TABLE 90 UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 91 UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 92 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 138 TABLE 93 FRANCE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 138 TABLE 94 FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 95 FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 96 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 140 TABLE 97 SPAIN: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 98 SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 99 SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 100 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 142 TABLE 101 ITALY: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 142 TABLE 102 ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 143 TABLE 103 ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 143 TABLE 104 REST OF EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 144 TABLE 105 REST OF EUROPE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 106 REST OF EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 145 TABLE 107 REST OF EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 145 TABLE 108 ASIA PACIFIC: TRANSPLANT VOLUME, 2024 147 TABLE 109 ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 110 ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 148 TABLE 111 ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 148 TABLE 112 ASIA PACIFIC: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 113 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 114 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 115 ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 150 TABLE 116 ASIA PACIFIC: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 117 ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 151 TABLE 118 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 152 TABLE 119 CHINA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 120 CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 121 CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 153 TABLE 122 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 154 TABLE 123 JAPAN: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 124 JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 125 JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 155 TABLE 126 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 156 TABLE 127 INDIA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 128 INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 129 INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 130 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 157 TABLE 131 SOUTH KOREA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 132 SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 133 SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 134 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 160 TABLE 135 AUSTRALIA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 136 AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 137 AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 138 REST OF ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 161 TABLE 139 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 140 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 141 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 142 LATIN AMERICA: TRANSPLANT VOLUME, 2024 164 TABLE 143 LATIN AMERICA: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 144 LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 164 TABLE 145 LATIN AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 165 TABLE 146 LATIN AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 147 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 148 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 149 LATIN AMERICA: HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 166 TABLE 150 LATIN AMERICA: HLA TYPING MARKET, BY DIAGNOSTIC APPLICATION, 2023–2030 (USD MILLION) 166 TABLE 151 LATIN AMERICA: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 167 TABLE 152 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 168 TABLE 153 BRAZIL: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 154 BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 155 BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 156 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 170 TABLE 157 MEXICO: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 158 MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 159 MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 160 REST OF LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 171 TABLE 161 REST OF LATIN AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 162 REST OF LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 163 REST OF LATIN AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 164 MIDDLE EAST & AFRICA: TRANSPLANT VOLUME, 2024 173 TABLE 165 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 166 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 174 TABLE 167 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 174 TABLE 168 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 169 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 170 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 171 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 176 TABLE 172 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY DIAGNOSTIC APPLICATION, 2023–2030 (USD MILLION) 176 TABLE 173 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 177 TABLE 174 GCC COUNTRIES: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 177 TABLE 175 GCC COUNTRIES: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 176 GCC COUNTRIES: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 177 GCC COUNTRIES: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 178 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 179 TABLE 179 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 180 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 181 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 182 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN HLA TYPING MARKET 182 TABLE 183 HLA TYPING MARKET: DEGREE OF COMPETITION 186 TABLE 184 HLA TYPING MARKET: REGION FOOTPRINT 193 TABLE 185 HLA TYPING MARKET: PRODUCT & SERVICE FOOTPRINT 194 TABLE 186 HLA TYPING MARKET: TECHNOLOGY FOOTPRINT 195 TABLE 187 HLA TYPING MARKET: APPLICATION FOOTPRINT 196 TABLE 188 HLA TYPING MARKET: END-USER FOOTPRINT 197 TABLE 189 HLA TYPING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 200 TABLE 190 HLA TYPING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 201 TABLE 191 HLA TYPING MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–APRIL 2025 202 TABLE 192 HLA TYPING MARKET: DEALS, JANUARY 2021–APRIL 2025 203 TABLE 193 HLA TYPING MARKET: EXPANSIONS, JANUARY 2021–APRIL 2025 205 TABLE 194 BD: COMPANY OVERVIEW 206 TABLE 195 BD: PRODUCTS OFFERED 207 TABLE 196 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW 209 TABLE 197 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 210 TABLE 198 THERMO FISHER SCIENTIFIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 211 TABLE 199 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–APRIL 2025 212 TABLE 200 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 212 TABLE 201 ILLUMINA, INC.: COMPANY OVERVIEW 214 TABLE 202 ILLUMINA, INC.: PRODUCTS OFFERED 215 TABLE 203 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 216 TABLE 204 QIAGEN: COMPANY OVERVIEW 218 TABLE 205 QIAGEN: PRODUCTS OFFERED 219 TABLE 206 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 221 TABLE 207 QIAGEN: DEALS, JANUARY 2021–APRIL 2025 222 TABLE 208 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 223 TABLE 209 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 224 TABLE 210 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 226 TABLE 211 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 227 TABLE 212 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 228 TABLE 213 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 229 TABLE 214 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2021–APRIL 2025 229 TABLE 215 CAREDX, INC.: COMPANY OVERVIEW 231 TABLE 216 CAREDX, INC.: PRODUCTS OFFERED 232 TABLE 217 CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 232 TABLE 218 CAREDX, INC.: DEALS, JANUARY 2022–APRIL 2025 233 TABLE 219 WERFEN: COMPANY OVERVIEW 234 TABLE 220 WERFEN: PRODUCTS OFFERED 234 TABLE 221 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 235 TABLE 222 WERFEN: DEALS, JANUARY 2022–APRIL 2025 235 TABLE 223 DIASORIN S.P.A.: COMPANY OVERVIEW 236 TABLE 224 DIASORIN S.P.A.: PRODUCTS OFFERED 237 TABLE 225 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 237 TABLE 226 TBG BIOTECHNOLOGY CORPORATION: COMPANY OVERVIEW 238 TABLE 227 TBG BIOTECHNOLOGY CORPORATION: PRODUCTS OFFERED 238 TABLE 228 TBG BIOTECHNOLOGY CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 239 TABLE 229 TBG BIOTECHNOLOGY CORPORATION: DEALS, JANUARY 2022–APRIL 2025 239 TABLE 230 FUJIREBIO: COMPANY OVERVIEW 240 TABLE 231 FUJIREBIO: PRODUCTS OFFERED 240 TABLE 232 FUJIREBIO: DEALS, JANUARY 2022–APRIL 2025 241 TABLE 233 EUROBIO SCIENTIFIC.: COMPANY OVERVIEW 242 TABLE 234 EUROBIO SCIENTIFIC: PRODUCTS OFFERED 243 TABLE 235 EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 243 TABLE 236 EUROBIO SCIENTIFIC: DEALS, JANUARY 2022–APRIL 2025 244 TABLE 237 PACBIO: COMPANY OVERVIEW 245 TABLE 238 PACBIO: PRODUCTS OFFERED 246 TABLE 239 PACBIO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 247 TABLE 240 PACBIO: DEALS, JANUARY 2022–APRIL 2025 247 TABLE 241 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW 248 TABLE 242 BAG DIAGNOSTICS GMBH: PRODUCTS OFFERED 248 TABLE 243 CREATIVE BIOLABS: COMPANY OVERVIEW 249 TABLE 244 CREATIVE BIOLABS: PRODUCTS OFFERED 249 TABLE 245 HISTOGENETICS LLC: COMPANY OVERVIEW 250 TABLE 246 SCISCO GENETICS, INC.: COMPANY OVERVIEW 251 TABLE 247 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW 252 TABLE 248 BIONOBIS: COMPANY OVERVIEW 253 TABLE 249 TAKARA BIO INC.: COMPANY OVERVIEW 254 TABLE 250 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW 255 TABLE 251 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW 256 TABLE 252 PROIMMUNE LTD.: COMPANY OVERVIEW 257 TABLE 253 BIOFORTUNA LIMITED: COMPANY OVERVIEW 258 TABLE 254 ALPHA BIOTECH LIMITED: COMPANY OVERVIEW 259 FIGURE 1 HLA TYPING MARKET SEGMENTATION AND REGIONAL SCOPE 27 FIGURE 2 HLA TYPING MARKET: YEARS CONSIDERED 28 FIGURE 3 HLA TYPING MARKET: RESEARCH DESIGN 30 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35 FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36 FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024 38 FIGURE 7 HLA TYPING MARKET: MARKET SIZE ESTIMATION METHODOLOGY 39 FIGURE 8 HLA TYPING MARKET: GROWTH PROJECTIONS BASED ON REVENUE IMPACT OF KEY MACRO INDICATORS 40 FIGURE 9 DATA TRIANGULATION 41 FIGURE 10 RESEARCH LIMITATIONS 43 FIGURE 11 HLA TYPING MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 44 FIGURE 12 HLA TYPING MARKET, BY PRODUCT &SERVICES, 2025 VS. 2030 (USD MILLION) 45 FIGURE 13 HLA TYPING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 45 FIGURE 14 HLA TYPING MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 46 FIGURE 15 GEOGRAPHIC SNAPSHOT OF HLA TYPING MARKET 47 FIGURE 16 GROWING NUMBER OF ORGAN TRANSPLANT PROCEDURES TO DRIVE MARKET 48 FIGURE 17 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49 FIGURE 18 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50 FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 57 FIGURE 20 AVERAGE SELLING PRICE OF INSTRUMENTS, 2024 (USD THOUSAND) 57 FIGURE 21 AVERAGE SELLING PRICE OF REAGENTS, 2024 (USD THOUSAND) 58 FIGURE 22 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD THOUSAND) 59 FIGURE 23 HLA TYPING MARKET: VALUE CHAIN ANALYSIS 60 FIGURE 24 HLA TYPING MARKET: SUPPLY CHAIN ANALYSIS 61 FIGURE 25 HLA TYPING MARKET: ECOSYSTEM ANALYSIS 62 FIGURE 26 INVESTMENTS AND FUNDING SCENARIO, 2019–2023 63 FIGURE 27 NUMBER OF DEALS IN MARKET, BY KEY PLAYER, 2019–2023 64 FIGURE 28 VALUE OF DEALS IN MARKET, BY KEY PLAYER, 2019–2023 (USD) 64 FIGURE 29 HLA TYPING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 67 FIGURE 30 HLA TYPING MARKET: IMPORT SCENARIO FOR HS CODE 3822, 2020–2024 69 FIGURE 31 HLA TYPING MARKET: EXPORT SCENARIO FOR HS CODE 3822, 2020–2024 70 FIGURE 32 HLA TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS 77 FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 79 FIGURE 34 KEY BUYING CRITERIA FOR END USERS 80 FIGURE 35 NORTH AMERICA: HLA TYPING MARKET SNAPSHOT 121 FIGURE 36 ASIA: HLA TYPING MARKET SNAPSHOT 146 FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING MARKET, 2020–2024 184 FIGURE 38 HLA TYPING MARKET SHARE ANALYSIS, 2024 185 FIGURE 39 EV/EBITDA OF KEY VENDORS 188 FIGURE 40 5-YEAR STOCK BETA OF KEY VENDORS 188 FIGURE 41 HLA TYPING MARKET: PRODUCT/BRAND COMPARISON 189 FIGURE 42 HLA TYPING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 191 FIGURE 43 HLA TYPING MARKET: COMPANY FOOTPRINT 192 FIGURE 44 HLA TYPING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 199 FIGURE 45 BD: COMPANY SNAPSHOT (2024) 207 FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 210 FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 215 FIGURE 48 QIAGEN: COMPANY SNAPSHOT (2024) 219 FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 224 FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 228 FIGURE 51 CAREDX, INC.: COMPANY SNAPSHOT (2024) 231 FIGURE 52 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024) 236 FIGURE 53 EUROBIO SCIENTIFIC: COMPANY SNAPSHOT (2024) 242 FIGURE 54 PACBIO: COMPANY SNAPSHOT (2022) 246

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們